BLSM Stock: Dilution, SEC Filings & News

BLSM BlossomHill Therapeutics, Inc.

Price$14.46

Company About

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

NASDAQ

Vol Avg.

202.66 K

Inst Own

0.000%

Float & OS

9.57 M / 31.78 M

Cash/Shr

$6.7

Market Cap & Ev

429.1 M / 351.01 M

Short Interest

5.1%

Borrow Rate

4.2016%

Days to Cover

2.87

Overall Offering Risk

Warrant Exercise Risk

Research Report

Customize research

Recent Articles (8)

View All

BlossomHill Therapeutics Announces Outcome from the End-of-Phase 1 Meeting with the FDA and Pivotal Phase 2 Trial Design for OMNI-EGFR™ Inhibitor, BH-30643, in EGFR C797S-Positive NSCLC

New

Globe Newswire

Nov 9, 2026, 7:00 AM

BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting

Globe Newswire

Nov 4, 2026, 7:00 AM

BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference

Globe Newswire

Nov 3, 2026, 7:00 AM

BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer

Globe Newswire

Oct 22, 2026, 7:00 AM

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

Globe Newswire

Sep 28, 2026, 7:00 AM

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

Globe Newswire

Sep 18, 2026, 7:00 AM

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

Globe Newswire

Sep 15, 2026, 7:00 AM

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

Globe Newswire

Sep 3, 2026, 7:00 AM

Recent Filings

View All

Type	Title	Date Released
10-Q	Form 10-Q	Sep 18, 2026, 7:30 AM
8-K	BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Pipeline Progress	Sep 18, 2026, 7:15 AM
8-K	BlossomHill Therapeutics Presents Updated Phase 1/2 SOLARA Trial Data for BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026	Sep 15, 2026, 7:30 AM
SCHEDULE 13D	ORBIMED ADVISORS LLC (Filed by)	Aug 18, 2026, 4:53 PM
SCHEDULE 13G	Vivo Innovation Fund II Holdings, L.P. (Filed by)	Aug 17, 2026, 3:46 PM
SCHEDULE 13G	PERCEPTIVE ADVISORS LLC (Filed by)	Aug 14, 2026, 5:18 PM
SCHEDULE 13D	Cormorant Asset Management, LP (Filed by)	Aug 13, 2026, 4:12 PM
4	GORDON CARL L (Reporting)	Aug 12, 2026, 4:46 PM
4	ORBIMED ADVISORS LLC (Reporting)	Aug 12, 2026, 4:43 PM
4	Schmid John P. (Reporting)	Aug 10, 2026, 6:35 PM
4	GORDON CARL L (Reporting)	Aug 10, 2026, 6:33 PM
4	Cormorant Asset Management, LP (Reporting)	Aug 10, 2026, 6:32 PM

Earnings

Dec

Q4 2026 Earnings reportUpcoming

Sep

Q3 2026 Earnings report

-8.75%missed

Related Healthcare stocks

All tickers

BlossomHill Therapeutics, Inc. BLSM

Related Healthcare stocks

Related Healthcare stocks